GRADE Recommendations for Antenatal Corticosteroids in the Late-Preterm Period
The Society for Maternal-Fetal Medicine (SMFM) assigns five distinct GRADE recommendations for late-preterm corticosteroid use, ranging from strong recommendations (GRADE 1A) for high-risk singleton pregnancies to conditional recommendations (GRADE 2C) for select populations not studied in the original trial. 1
Breakdown of GRADE Assignments
GRADE 1A - Strongest Recommendation
- Offer a single course of antenatal corticosteroids (2 doses of 12 mg intramuscular betamethasone 24 hours apart) to patients meeting ALPS trial criteria:
- Singleton pregnancy between 34 0/7 and 36 6/7 weeks
- High risk of preterm birth within next 7 days and before 37 weeks
- This represents high-quality evidence with strong recommendation 1
GRADE 2C - Conditional Recommendation
- Consider use in select populations not included in the original ALPS trial:
- Multiple gestations reduced to singleton on or after 14 0/7 weeks
- Patients with fetal anomalies
- Those expected to deliver in <12 hours
- This reflects low-quality evidence with weak recommendation 1
GRADE 1B - Strong Recommendation Against
- Do not use antenatal corticosteroids in pregnant patients with low likelihood of delivery before 37 weeks
- Moderate-quality evidence supporting strong recommendation against use 1
GRADE 1C - Strong Recommendation Against (Specific Population)
- Do not use late preterm corticosteroids in pregnant patients with pregestational diabetes mellitus
- Risk of worsening neonatal hypoglycemia outweighs benefits
- Low-quality evidence but strong recommendation due to safety concerns 1
GRADE 1C - Strong Recommendation for Counseling
- Thoroughly counsel patients at risk for late preterm delivery regarding:
- Potential risks and benefits of corticosteroid administration
- Long-term risks remain uncertain
- Low-quality evidence but strong recommendation for informed consent 1
Understanding the GRADE System in This Context
The GRADE system used here reflects:
- Number (1 or 2): Strength of recommendation (1 = strong, 2 = conditional)
- Letter (A, B, or C): Quality of evidence (A = high, B = moderate, C = low)
The strongest evidence (GRADE 1A) applies specifically to the ALPS trial population, which demonstrated clear reduction in respiratory morbidity with betamethasone versus placebo (11.6% vs 14.4%; RR 0.80) and severe respiratory morbidity (8.1% vs 12.1%; RR 0.67) 1.
Key Clinical Caveat
The GRADE 1C recommendation against use in pregestational diabetes is particularly important—despite being based on lower-quality evidence, the strong recommendation reflects the known increased risk of neonatal hypoglycemia in this population, which has been independently associated with developmental delays in preschool-aged children 1. Women with pregestational diabetes were explicitly excluded from the ALPS trial, yet many practitioners began administering late preterm steroids to this population after trial publication 1.